Novo Nordisk: Brussels approves acquisition

(CercleFinance.com) - Novo Nordisk has announced that the European Commission has approved the acquisition by Novo Holdings of Catalent, a US contract development and manufacturing company, and the subsequent purchase by Novo Nordisk of three plants from Novo Holdings.


The agreement to acquire the three production sites was announced on 5 February. On 29 May, Catalent shareholders voted in favour of the current transaction. In addition, the transaction has been approved by the authorities in a number of jurisdictions.

Completion of the acquisition remains subject to other customary closing conditions, including regulatory approvals in other jurisdictions. Novo Nordisk still expects the transaction to close towards the end of 2024.


Copyright (c) 2024 CercleFinance.com. All rights reserved.